Developer docs
API playgroundTry for free, no card

Search company profiles

Trait Biosciences

Full company profile

uuid0002fa7

Namestring
Trait Biosciences
Legal namestring
Trait Biosciences Inc.
Websiteurl
traitbio.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Trait Biosciences is a cannabis biotechnology company founded in 2017 and headquartered in Santa Fe, New Mexico, with research operations in Los Alamos, NM and Toronto, Canada. The company has developed a proprietary enzymatic glycosylation process that converts water-insoluble hemp-derived cannabinoids (CBD, THC, and others) into fully water-soluble, free-flowing powder forms exceeding 97% purity, marketed under lead molecule CBD82S (Cannabindyl diglucoside / GlyCBD). Unlike nanoemulsions or emulsions, the technology produces true aqueous solutions that eliminate the need for oils, surfactants, or added particles, and has demonstrated 300x faster intestinal permeation, 10x higher epithelial transport, and 100x faster transdermal penetration versus conventional CBD in tissue studies.

The company commercializes these actives through a multi-brand B2B ingredient portfolio: Trait Distilled for beverages and ingestibles, Trait VitaComplex for pharmaceutical and OTC APIs, Trait GlycoRenew for cosmeceuticals and topicals, and Trait Companion for pet health applications. The technology platform is protected by 90+ patents held, applied for, or licensed, with additional IP covering the Trait Amplified hemp plant transformation technology that increases trichome density by at least 30% and total cannabinoid output by approximately 200% (400% for select cannabinoids). Revenue mechanics combine B2B ingredient supply agreements with technology licensing/royalties; products are manufactured under pharma-GMP quality standards and positioned for global supply chains.

The business is supported by a leadership team combining deep CPG, pharmaceutical, and plant science expertise, including CSO Dr. Richard Sayre (recognized by Nature among the "top five crop researchers who could change the world") and President/COO Dr. Hanny Kanafani (prior leadership at PepsiCo, Herbalife, MeadJohnson, and Pillsbury), backed by an advisory bench drawn from Mars Wrigley, Bacardi, Anheuser-Busch, Diageo, IFF, and Vanderbilt. Key institutional investors are Btomorrow Ventures (British American Tobacco's CVC) and Gotham Green Partners, both of which hold board representation and have led successive financing rounds since 2021.

Short descriptiontext

Trait Biosciences is a cannabis biotechnology company that develops proprietary water-soluble cannabinoid ingredients via enzymatic glycosylation. It supplies pharma-grade CBD, THC, and cannabinoid APIs to consumer brands, pharmaceutical developers, and manufacturers across beverages, cosmeceuticals, therapeutics, and pet health.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSanta Fe, United States
HQ citystring
Santa Fe
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
water-soluble cannabinoids, cannabis biotechnology, pharmaceutical cannabinoid APIs, cosmeceutical CBD ingredients, pet health cannabinoid APIs
Industry5 codes
PRIMARYCRAOAIAG
Hemp & CBD Product Wholesale Distribution
Consumer Products & Retail/Wholesale, Distribution & Category Management/Alcohol, Tobacco & Cannabis Wholesale Distribution
SECONDARYCRANAHAA
CBD/Hemp Specialty Stores (Tinctures, Oils, Edibles)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
SECONDARYCRANAHAC
CBD/Hemp Wellness & Supplements Retail
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
SECONDARYCRANAHAB
CBD/Hemp Topicals & Beauty Retail
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
SECONDARYCRANAHAF
CBD/Hemp Pet Products Retail
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
NAICS code2 codes
  • Medicinal and Botanical Manufacturing325411
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Pharmaceutical Preparations2834
Product category
Cannabis Biotechnology Ingredients
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Ingredient / B2B Ingredient Sales
TypeOne Time License
Description

Trait Biosciences sells its proprietary water-soluble cannabinoid ingredients (GlyCBD, CBD82S, and branded product lines) as pharma-grade active ingredients to B2B customers including consumer product brands, contract manufacturers, and go-to-market partners. Revenue is generated through ingredient supply agreements with finished goods manufacturers across beverages, nutraceuticals, cosmeceuticals, OTC/Rx therapeutics, and pet health categories. The company positions its ingredients as enabling partners to accelerate product development timelines.

traitbio.com
2Technology Licensing
TypeLicensing Royalties
Description

Trait licenses its patent-protected water-soluble cannabinoid technologies and production processes to commercial partners. The company's IP portfolio (90+ patents) supports licensing arrangements for manufacturing and commercialization rights, enabling partners to build competitive advantage using Trait's technology platform.

traitbio.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Trait Distilled™
Description

Water-soluble CBD ingredient brand for ingestible consumer products including beverages, gummies, and supplements. Enables full dissolution, precise dosing, even distribution, and stable incorporation across diverse oral formats.

traitbio.com
+4 more records
Core offering1 text field

Trait Biosciences converts water-insoluble hemp-derived cannabinoids (CBD, THC, and others) into fully water-soluble, free-flowing white powders (>97% purity) using proprietary enzymatic glycosylation technology. The company sells these patent-protected, pharma-GMP manufactured cannabinoid ingredients under four branded product lines (Distilled, VitaComplex, GlycoRenew, Companion) to B2B customers developing finished products in beverages, nutraceuticals, cosmeceuticals, OTC/Rx therapeutics, and pet health.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 300× higher intestinal permeation vs. conventional CBD (ex vivo testing)
+7 more records
Product overview1 text field

Trait Biosciences is a biotechnology company that has developed a proprietary glycosylation technology to transform water-insoluble cannabinoids (naturally lipophilic) into truly water-soluble forms. The company operates a multi-brand portfolio architecture: Trait Distilled™ serves consumer ingestibles (beverages, gummies, supplements); Trait VitaComplex targets pharmaceutical/OTC applications; Trait Glycorenew addresses cosmeceuticals and topical skincare; and Trait Companion focuses on companion animal health. The lead commercial molecule is GlyCBD™ (within the Distilled™ brand), with CBD82S (Cannabildyl diglucoside) as a key research-grade compound. All offerings are manufactured under pharma-GMP quality standards and are patent-protected.

Product and service6 records
1Trait Distilled
CategoryWater-soluble CBD ingredient (B2B)
Description

Water-soluble CBD ingredient brand for consumer ingestible products including beverages, gummies, chewables, and supplements. Enables full dissolution, precise dosing, even distribution, and stable incorporation across diverse oral formats without oils, emulsifiers, or added particles.

2Trait VitaComplex
CategoryPharmaceutical-grade cannabinoid API
Description

Proprietary line of structurally modified, water-soluble cannabinoid Active Pharmaceutical Ingredients (APIs) for pharmaceutical applications. Delivers ~300x higher intestinal permeation and ~10x higher epithelial transport vs. conventional CBD, supporting oral, topical, injectable, and inhalable routes for OTC and prescription drug development.

3Trait GlycoRenew
CategoryCosmeceutical CBD ingredient
Description

Water-soluble CBD ingredient specifically innovated for topical and cosmetic skin applications. Enables true aqueous solutions for sprays, serums, and shampoos with ~100x higher skin absorption vs. conventional CBD and eliminates emulsion stability risks.

4Trait Companion
CategoryAnimal health CBD ingredient
Description

Water-soluble CBD ingredient developed for companion animal health applications (dogs and cats). Validated in in vitro and in vivo studies showing ~300x higher intestinal permeation; enables oral tablets/chews, liquid formulations, and topical applications with more predictable therapeutic efficacy.

5GlyCBD
CategoryWater-soluble CBD molecule
Description

Lead commercial pharma-grade, water-soluble CBD molecule within the Trait Distilled brand. Delivers efficient absorption and consistent performance across ingestible, topical, oral/intranasal mucosal, and inhalable applications.

6CBD82S (Cannabindyl diglucoside)
CategoryWater-soluble CBD API compound
Description

Proprietary glycosylated water-soluble CBD compound (Cannabindyl diglucoside) created by enzymatic addition of glucose to hemp-derived CBD. High purity (>97%), free-flowing white powder with 300x faster intestinal permeation, 10x higher epithelial transport, and 100x faster transdermal penetration vs. conventional CBD; supports oral, topical, inhalable, and injectable delivery.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-10-12
Description

The October 2023 financing specifically states that proceeds will support Trait's partnerships with contract manufacturers and go-to-market partners. This enables the commercialization and scaling of Trait's water-soluble CBD ingredients into finished consumer products across target markets.

Strategic tierMinorTypeOthersAnnounced on2018-10-08
Description

Executives Joseph del Moral, Hannan Fleiman, and Ronan Levy, who led the seed financing round and joined Trait's executive team in 2018, previously founded CanvasRx Inc., which was acquired by Aurora Cannabis Inc. in 2016. No direct commercial partnership between Trait and Aurora is explicitly described in the sources.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Lexaria Bioscience develops its proprietary DehydraTECH technology to enhance the bioavailability and delivery of cannabinoids and other lipophilic active ingredients. Both companies are B2B technology platforms focused on water-soluble/bioavailability-enhanced cannabinoid APIs serving pharmaceutical, nutraceutical, and consumer product customers.

TypeDirect peer
Description

MediPharm Labs is a B2B cannabis extraction and ingredient supplier producing cannabis concentrates and derivative APIs for third-party brands. Like Trait, MediPharm operates a white-label/manufacturer model supplying cannabinoids to consumer product companies rather than competing in retail.

TypeBroad incumbent
Description

GW Pharmaceuticals pioneered FDA-approved cannabinoid therapeutics (Epidiolex) and was acquired by Jazz Pharmaceuticals in 2021. Jazz/GW represents the validated endgame for cannabinoid pharma — a relevant incumbent benchmark for Trait's VitaComplex Rx API ambitions, though vastly larger and more diversified.

4Botanix Pharmaceuticals Limited
TypeDirect peer
Description

Botanix Pharmaceuticals is a clinical-stage cannabinoid pharmaceutical company developing prescription treatments using synthetic CBD for skin and systemic conditions. Directly comparable as a small-cap cannabinoid pharma peer pursuing FDA-regulated Rx pathways with proprietary CBD formulations.

TypeEmerging player
Description

Zynerba Pharmaceuticals develops transdermal synthetic cannabinoid therapeutics for rare neurological and psychiatric conditions. Comparable as a small emerging player in cannabinoid drug delivery with similar regulatory pathway exposure and pipeline-stage execution risk.

TypeEmerging player
Description

Cardiol Therapeutics is developing pharmaceutical-grade cannabinoid formulations targeting inflammatory heart disease. Comparable as a clinical-stage cannabinoid pharma peer with similar Rx development focus and small-cap public company profile.

TypeDirect peer
Description

Cure Pharmaceutical developed drug delivery platforms for cannabinoids before being acquired by Berkshire Sterile Manufacturing. Comparable as a B2B cannabis drug delivery technology company focused on improved bioavailability and formulation, similar in technical positioning to Trait's glycosylation platform.

TypeBroad incumbent
Description

Charlotte's Web is the largest US CBD wellness brand offering tinctures, gummies, topicals, and pet products. While vertically integrated into retail rather than B2B, Charlotte's Web is a key downstream buyer of CBD ingredients and a benchmark for the end-markets Trait Distilled and Trait Companion serve.

TypeBroad incumbent
Description

cbdMD is a leading US CBD consumer brand offering topicals, tinctures, gummies, and pet products. Comparable as a multi-vertical CBD brand operating in the same ingestible, topical, and pet end-markets that Trait's branded ingredients supply.

10Tilray Brands, Inc.
TypeBroad incumbent
Description

Tilray is a global cannabis operator with medical, wellness, and beverage operations across multiple continents. Comparable as a broad incumbent in the cannabis industry whose Canadian/Australian medical divisions overlap with Trait's pharma/cannabinoid API ambitions, though much larger and retail-distribution focused.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Trait Biosciences

Cannabis Biotechnology Ingredientstraitbio.com

Trait Biosciences is a cannabis biotechnology company that develops proprietary water-soluble cannabinoid ingredients via enzymatic glycosylation. It supplies pharma-grade CBD, THC, and cannabinoid APIs to consumer brands, pharmaceutical developers, and manufacturers across beverages, cosmeceuticals, therapeutics, and pet health.

What Trait Biosciences does

Trait Biosciences is a cannabis biotechnology company founded in 2017 and headquartered in Santa Fe, New Mexico, with research operations in Los Alamos, NM and Toronto, Canada. The company has developed a proprietary enzymatic glycosylation process that converts water-insoluble hemp-derived cannabinoids (CBD, THC, and others) into fully water-soluble, free-flowing powder forms exceeding 97% purity, marketed under lead molecule CBD82S (Cannabindyl diglucoside / GlyCBD). Unlike nanoemulsions or emulsions, the technology produces true aqueous solutions that eliminate the need for oils, surfactants, or added particles, and has demonstrated 300x faster intestinal permeation, 10x higher epithelial transport, and 100x faster transdermal penetration versus conventional CBD in tissue studies.

The company commercializes these actives through a multi-brand B2B ingredient portfolio: Trait Distilled for beverages and ingestibles, Trait VitaComplex for pharmaceutical and OTC APIs, Trait GlycoRenew for cosmeceuticals and topicals, and Trait Companion for pet health applications. The technology platform is protected by 90+ patents held, applied for, or licensed, with additional IP covering the Trait Amplified hemp plant transformation technology that increases trichome density by at least 30% and total cannabinoid output by approximately 200% (400% for select cannabinoids). Revenue mechanics combine B2B ingredient supply agreements with technology licensing/royalties; products are manufactured under pharma-GMP quality standards and positioned for global supply chains.

The business is supported by a leadership team combining deep CPG, pharmaceutical, and plant science expertise, including CSO Dr. Richard Sayre (recognized by Nature among the "top five crop researchers who could change the world") and President/COO Dr. Hanny Kanafani (prior leadership at PepsiCo, Herbalife, MeadJohnson, and Pillsbury), backed by an advisory bench drawn from Mars Wrigley, Bacardi, Anheuser-Busch, Diageo, IFF, and Vanderbilt. Key institutional investors are Btomorrow Ventures (British American Tobacco's CVC) and Gotham Green Partners, both of which hold board representation and have led successive financing rounds since 2021.

Trait Biosciences firmographics

Firmographics
Name
Trait Biosciences
Legal name
Trait Biosciences Inc.
Website
https://traitbio.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Trait Biosciences is a cannabis biotechnology company that develops proprietary water-soluble cannabinoid ingredients via enzymatic glycosylation. It supplies pharma-grade CBD, THC, and cannabinoid APIs to consumer brands, pharmaceutical developers, and manufacturers across beverages, cosmeceuticals, therapeutics, and pet health.
Ownership category
akta.pro rank

Trait Biosciences industry classification

Industry
Product category
Cannabis Biotechnology Ingredients
NAICS
Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412)
SIC
Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYCRAOAIAG
Hemp & CBD Product Wholesale Distribution
Consumer Products & Retail/Wholesale, Distribution & Category Management/Alcohol, Tobacco & Cannabis Wholesale Distribution
SECONDARYCRANAHAA
CBD/Hemp Specialty Stores (Tinctures, Oils, Edibles)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
SECONDARYCRANAHAC
CBD/Hemp Wellness & Supplements Retail
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
SECONDARYCRANAHAB
CBD/Hemp Topicals & Beauty Retail
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
SECONDARYCRANAHAF
CBD/Hemp Pet Products Retail
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)

Keywords

  • Water-soluble cannabinoids
  • Cannabis biotechnology
  • Pharmaceutical cannabinoid APIs
  • Cosmeceutical CBD ingredients
  • Pet health cannabinoid APIs

Where Trait Biosciences is headquartered

Location

Headquarters

HQ city
Santa Fe
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Trait Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Ingredient / B2B Ingredient Sales: Trait Biosciences sells its proprietary water-soluble cannabinoid ingredients (GlyCBD, CBD82S, and branded product lines) as pharma-grade active ingredients to B2B customers including consumer product brands, contract manufacturers, and go-to-market partners. Revenue is generated through ingredient supply agreements with finished goods manufacturers across beverages, nutraceuticals, cosmeceuticals, OTC/Rx therapeutics, and pet health categories. The company positions its ingredients as enabling partners to accelerate product development timelines.
  2. Technology Licensing: Trait licenses its patent-protected water-soluble cannabinoid technologies and production processes to commercial partners. The company's IP portfolio (90+ patents) supports licensing arrangements for manufacturing and commercialization rights, enabling partners to build competitive advantage using Trait's technology platform.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Trait Biosciences product offering

Product offering

Core offering

Trait Biosciences converts water-insoluble hemp-derived cannabinoids (CBD, THC, and others) into fully water-soluble, free-flowing white powders (>97% purity) using proprietary enzymatic glycosylation technology. The company sells these patent-protected, pharma-GMP manufactured cannabinoid ingredients under four branded product lines (Distilled, VitaComplex, GlycoRenew, Companion) to B2B customers developing finished products in beverages, nutraceuticals, cosmeceuticals, OTC/Rx therapeutics, and pet health.

Product overview

Trait Biosciences is a biotechnology company that has developed a proprietary glycosylation technology to transform water-insoluble cannabinoids (naturally lipophilic) into truly water-soluble forms. The company operates a multi-brand portfolio architecture: Trait Distilled™ serves consumer ingestibles (beverages, gummies, supplements); Trait VitaComplex targets pharmaceutical/OTC applications; Trait Glycorenew addresses cosmeceuticals and topical skincare; and Trait Companion focuses on companion animal health. The lead commercial molecule is GlyCBD™ (within the Distilled™ brand), with CBD82S (Cannabildyl diglucoside) as a key research-grade compound. All offerings are manufactured under pharma-GMP quality standards and are patent-protected.

Differentiator

Problem solved

Functional benefit

Brands

  • Trait Distilled™: Water-soluble CBD ingredient brand for ingestible consumer products including beverages, gummies, and supplements. Enables full dissolution, precise dosing, even distribution, and stable incorporation across diverse oral formats.
  • Trait VitaComplex
  • Trait GlycoRenew
  • Trait Companion
  • GlyCBD™

Products and services

  • Trait Distilled Water-soluble CBD ingredient brand for consumer ingestible products including beverages, gummies, chewables, and supplements. Enables full dissolution, precise dosing, even distribution, and stable incorporation across diverse oral formats without oils, emulsifiers, or added particles.
  • Trait VitaComplex Proprietary line of structurally modified, water-soluble cannabinoid Active Pharmaceutical Ingredients (APIs) for pharmaceutical applications. Delivers ~300x higher intestinal permeation and ~10x higher epithelial transport vs. conventional CBD, supporting oral, topical, injectable, and inhalable routes for OTC and prescription drug development.
  • Trait GlycoRenew Water-soluble CBD ingredient specifically innovated for topical and cosmetic skin applications. Enables true aqueous solutions for sprays, serums, and shampoos with ~100x higher skin absorption vs. conventional CBD and eliminates emulsion stability risks.
  • Trait Companion Water-soluble CBD ingredient developed for companion animal health applications (dogs and cats). Validated in in vitro and in vivo studies showing ~300x higher intestinal permeation; enables oral tablets/chews, liquid formulations, and topical applications with more predictable therapeutic efficacy.
  • GlyCBD Lead commercial pharma-grade, water-soluble CBD molecule within the Trait Distilled brand. Delivers efficient absorption and consistent performance across ingestible, topical, oral/intranasal mucosal, and inhalable applications.
  • CBD82S (Cannabindyl diglucoside) Proprietary glycosylated water-soluble CBD compound (Cannabindyl diglucoside) created by enzymatic addition of glucose to hemp-derived CBD. High purity (>97%), free-flowing white powder with 300x faster intestinal permeation, 10x higher epithelial transport, and 100x faster transdermal penetration vs. conventional CBD; supports oral, topical, inhalable, and injectable delivery.

Quantifiable outcome

  • 300× higher intestinal permeation vs. conventional CBD (ex vivo testing)
  • +7 more outcomes

Companies that use Trait Biosciences

Customer profile

Segments4 records

Ideal customer profiles4 records

Trait Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Trait Biosciences partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Contract Manufacturers and Go-to-Market PartnerscoreChannel Partner/ Reseller/ Distributor · 12 October 2023The October 2023 financing specifically states that proceeds will support Trait's partnerships with contract manufacturers and go-to-market partners. This enables the commercialization and scaling of Trait's water-soluble CBD ingredients into finished consumer products across target markets.
  • Aurora Cannabis Inc.minorOthers · 8 October 2018Executives Joseph del Moral, Hannan Fleiman, and Ronan Levy, who led the seed financing round and joined Trait's executive team in 2018, previously founded CanvasRx Inc., which was acquired by Aurora Cannabis Inc. in 2016. No direct commercial partnership between Trait and Aurora is explicitly described in the sources.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Trait Biosciences competitors and assessment

Company assessment

Direct peers

  • Lexaria Bioscience Corp. Lexaria Bioscience develops its proprietary DehydraTECH technology to enhance the bioavailability and delivery of cannabinoids and other lipophilic active ingredients. Both companies are B2B technology platforms focused on water-soluble/bioavailability-enhanced cannabinoid APIs serving pharmaceutical, nutraceutical, and consumer product customers.
  • MediPharm Labs Corp. MediPharm Labs is a B2B cannabis extraction and ingredient supplier producing cannabis concentrates and derivative APIs for third-party brands. Like Trait, MediPharm operates a white-label/manufacturer model supplying cannabinoids to consumer product companies rather than competing in retail.
  • Botanix Pharmaceuticals Limited: Botanix Pharmaceuticals is a clinical-stage cannabinoid pharmaceutical company developing prescription treatments using synthetic CBD for skin and systemic conditions. Directly comparable as a small-cap cannabinoid pharma peer pursuing FDA-regulated Rx pathways with proprietary CBD formulations.
  • Cure Pharmaceutical (now Berkshire Sterile Manufacturing): Cure Pharmaceutical developed drug delivery platforms for cannabinoids before being acquired by Berkshire Sterile Manufacturing. Comparable as a B2B cannabis drug delivery technology company focused on improved bioavailability and formulation, similar in technical positioning to Trait's glycosylation platform.

Broad incumbents

  • GW Pharmaceuticals (Jazz Pharmaceuticals): GW Pharmaceuticals pioneered FDA-approved cannabinoid therapeutics (Epidiolex) and was acquired by Jazz Pharmaceuticals in 2021. Jazz/GW represents the validated endgame for cannabinoid pharma — a relevant incumbent benchmark for Trait's VitaComplex Rx API ambitions, though vastly larger and more diversified.
  • Charlotte's Web Holdings: Charlotte's Web is the largest US CBD wellness brand offering tinctures, gummies, topicals, and pet products. While vertically integrated into retail rather than B2B, Charlotte's Web is a key downstream buyer of CBD ingredients and a benchmark for the end-markets Trait Distilled and Trait Companion serve.
  • cbdMD, Inc. cbdMD is a leading US CBD consumer brand offering topicals, tinctures, gummies, and pet products. Comparable as a multi-vertical CBD brand operating in the same ingestible, topical, and pet end-markets that Trait's branded ingredients supply.
  • Tilray Brands, Inc. Tilray is a global cannabis operator with medical, wellness, and beverage operations across multiple continents. Comparable as a broad incumbent in the cannabis industry whose Canadian/Australian medical divisions overlap with Trait's pharma/cannabinoid API ambitions, though much larger and retail-distribution focused.

Emerging players

  • Zynerba Pharmaceuticals: Zynerba Pharmaceuticals develops transdermal synthetic cannabinoid therapeutics for rare neurological and psychiatric conditions. Comparable as a small emerging player in cannabinoid drug delivery with similar regulatory pathway exposure and pipeline-stage execution risk.
  • Cardiol Therapeutics: Cardiol Therapeutics is developing pharmaceutical-grade cannabinoid formulations targeting inflammatory heart disease. Comparable as a clinical-stage cannabinoid pharma peer with similar Rx development focus and small-cap public company profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Trait Biosciences social profiles

Digital presence

Trait Biosciences compliance and trust

Trust signal

Compliance1 record

Trait Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Trait Biosciences leadership team

Management profile

Number of profiles

Profiles1 record

Trait Biosciences funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Trait Biosciences M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Trait Biosciences

What does Trait Biosciences do?

Trait Biosciences converts water-insoluble hemp-derived cannabinoids (CBD, THC, and others) into fully water-soluble, free-flowing white powders (>97% purity) using proprietary enzymatic glycosylation technology. The company sells these patent-protected, pharma-GMP manufactured cannabinoid ingredients under four branded product lines (Distilled, VitaComplex, GlycoRenew, Companion) to B2B customers developing finished products in beverages, nutraceuticals, cosmeceuticals, OTC/Rx therapeutics, and pet health.

Is Trait Biosciences a public or private company?

Trait Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Trait Biosciences founded?

Trait Biosciences was founded in 2017. It employs 11 to 50 people.

Where is Trait Biosciences based?

Trait Biosciences is headquartered in Santa Fe, United States, in the North America region.

How does Trait Biosciences make money?

Two revenue lines are on record. Ingredient / B2B Ingredient Sales are the primary driver. The others are technology Licensing.

Who are Trait Biosciences's main competitors?

Direct peers on record are Lexaria Bioscience Corp., MediPharm Labs Corp., Botanix Pharmaceuticals Limited and Cure Pharmaceutical (now Berkshire Sterile Manufacturing). Broad incumbents are GW Pharmaceuticals (Jazz Pharmaceuticals), Charlotte's Web Holdings, cbdMD, Inc. and Tilray Brands, Inc.. Emerging players are Zynerba Pharmaceuticals and Cardiol Therapeutics.

Does Trait Biosciences have an API?

No public API is recorded for Trait Biosciences.

What industry is Trait Biosciences in?

Trait Biosciences's product category is Cannabis Biotechnology Ingredients. Its primary akta.pro industry code is CRAOAIAG, Hemp & CBD Product Wholesale Distribution, with a secondary code of CRANAHAA, CBD/Hemp Specialty Stores (Tinctures, Oils, Edibles). Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireTrait Biosciences' CBD82S™ Demonstrates Greater Metabolic Stability in a Human Liver Microsome ModelTrait Biosciences reported that its water-soluble CBD82S showed a 25-fold longer apparent half-life than conventional CBD in a human liver microsome model. The greater metabolic stability suggests improved dose utilization and delivery, though further studies are needed to confirm pharmacokinetic performance.EIN PresswireTrait Biosciences' CBD82S™ Demonstrates Greater Metabolic Stability in a Human Liver Microsome ModelTrait Biosciences reported that its CBD82S ingredient showed an approximately 25-fold longer apparent half-life than conventional CBD in a human liver microsome model. The findings indicate greater metabolic stability, suggesting improved dose utilization and delivery. Further studies are needed to translate this into pharmacokinetic performance.EIN PresswireWater-Soluble CBD82S™ Demonstrates Enhanced Presence in Brain Tissue in Both Active Form and as a PrecursorTrait Biosciences reported preclinical findings showing CBD82S and native CBD in brain tissue after topical administration. The water-soluble CBD82S may act as a reservoir, enabling sustained release of native CBD. Future research will evaluate concentrations over time.EIN PresswireTrait Biosciences highlights CBD82S™ anxiety-reducing potential using its water-soluble CBD technology platformTrait Biosciences highlighted preclinical findings showing that its proprietary water-soluble CBD ingredient, CBD82S™, reduced anxiety-like behavior in mouse models. The company states that this technology improves bioavailability and consistency compared to conventional CBD, addressing key barriers in cannabinoid delivery for human and animal health applications.EIN PresswireTrait Biosciences Reports Findings from Water-Soluble Cannabidiol (CBD) Formulation in Companion AnimalsTrait Biosciences reported findings from a 14-day in-home evaluation of its water-soluble CBD82S ingredient applied topically to companion animals with mobility limitations. Owners reported changes in ease of movement, activity levels, and comfort-related behavior. The company states the technology improves CBD's aqueous solubility and formulation consistency.Petfood IndustryTrait Biosciences highlights improved pet joint health with water-soluble CBDTrait Biosciences announced positive results from an exploratory in-home evaluation of its water-soluble CBD ingredient, CBD82S™, for improving joint health and mobility in dogs and cats. The study indicated that pet owners observed noticeable improvements in comfort and activity levels within the first week of a 14-day testing period.TraitbioTrait Biosciences closes on financing led by BAT’s Btomorrow Ventures and Gotham Green Partners and advances commercialization of unique water-soluble cannabinoidsTrait Biosciences has closed a financing round led by Btomorrow Ventures, the corporate venture capital arm of British American Tobacco (BAT), and Gotham Green Partners. The funding supports the commercialization of its water-soluble cannabinoid technology, with a launch of first-generation water-soluble CBD expected in the first quarter of 2024.FinSMEsTrait Biosciences Closes Financing RoundTrait Biosciences has closed a funding round led by Btomorrow Ventures and Gotham Green Partners to support the development and commercialization of its water-soluble cannabinoid technologies. The company plans to utilize these funds for partnerships with manufacturers and go-to-market entities, anticipating the launch of its first-generation water-soluble CBD in the first quarter of 2024.